Nuformix PLC Appointment of Broker (4400J)
22 Diciembre 2020 - 1:00AM
UK Regulatory
TIDMNFX
RNS Number : 4400J
Nuformix PLC
22 December 2020
22 December 2020
Nuformix plc
(the "Company" or the "Group")
Appointment of Broker
Nuformix plc (LSE:NFX), a drug re-purposing specialist, is
pleased to announce the appointment of Allenby Capital Limited as
the Company's sole Broker with effect from today.
Allenby Capital currently advise over 60 corporate clients
listed on the London Stock Exchange main market, AIM or Aquis
exchanges. Allenby Capital will provide access for Nuformix to a
broad spectrum of investors including institutional investors,
family offices, private client brokers and high net worth
individuals.
Enquiries:
Nuformix plc +44 (0)1223 627222
Dr Anne Brindley, CEO
Fleur Wood, Investor Relations
Email: fleur.wood@nuformix.com
Allenby Capital Limited +44 (0)20 3328 5656
Tim Sohal / Matt Butlin (Sales and Corporate
Broking)
Nick Athanas (Corporate Finance)
About Nuformix plc:
Nuformix is a pharmaceutical development company focused on
unlocking the therapeutic potential and value of known drugs to
develop new novel medicines which provide therapeutic and
commercial advantages to the currently available drug form.
Nuformix's model of repurposing drugs utilises many technologies
but is focussed on its acknowledged expertise in the use of
cocrystal technology through which the Group has developed and
patented novel forms of small molecules. Its platform is not
therapy-specific but instead has broad application across a wide
range of indications. Using its technology, the Group is developing
proprietary medicines for its own development pipeline and in
partnership with pharmaceutical and biotech companies.
Nuformix plc shares are traded on the London Stock Exchange's
Official List under the ticker: NFX. For more information please
visit www.nuformix.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
APPFEUFAFESSEDE
(END) Dow Jones Newswires
December 22, 2020 02:00 ET (07:00 GMT)
Nuformix (LSE:NFX)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Nuformix (LSE:NFX)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024